The Latest Cardiac and Vascular News
SALT LAKE CITY–(BUSINESS WIRE)–Heart valve innovator Foldax®, a company reinventing every aspect of the heart valve, from material to design to manufacturing, today announced the closing of a $20 million Series D round of funding. MemorialCare Innovation Fund (MCIF) led the round, with Angel Physicians Fund (APF) and Sayan Bioventures joining […]
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected its Tria™ LifePolymer™ heart valve technology […]
Company demonstrates excellent progress in its surgical aortic heart valve study SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that it has completed initial enrollment in its early feasibility study (EFS) for the Tria LifePolymer™ heart valve. Fifteen patients have been enrolled in 4 participating sites. “The study is progressing well and we […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that Tria LifePolymer™ heart valve technology was honored with The Best Innovation Award at the 2020 Cardiovascular Research Technologies (CRT) meeting in National Harbor, MD. The presentation, titled “Foldax Tria First in Human Implant of a Totally Synthetic Polymeric Aortic Heart Valve,” was given […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that Tria LifePolymer™ heart valve technology was honored with The Best Innovation Award at the 2020 Cardiovascular Research Technologies (CRT) meeting in National Harbor, MD. The presentation, titled “Foldax Tria First in Human Implant of a Totally Synthetic Polymeric Aortic Heart Valve,” was given […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for the treatment of aortic valve disease. Clinicians at Beaumont Hospital, Royal Oak, in Michigan, implanted this innovative flexible polymer heart valve, which has the potential to address […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease. Using breakthrough LifePolymer™ – a proprietary advanced biopolymer material – and […]
